Both SETD8 binding domain and methyltransferase activity are essential for PRDM2 tumor suppressor function, and frameshift mutations resulting in a truncated protein incapable of binding SETD8 are a frequent hallmark of various aggressive cancers [70]. This evidence concerns the gene KMT5A and cancer.